Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cicloprofen is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid derivative class, chemically identified as a fluorene derivative. It functions primarily as an inhibitor of the cyclooxygenase (COX) enzymes, thereby blocking the synthesis of prostaglandins that mediate pain, inflammation, and fever. Historically developed by Squibb (as SQ 20824) for the treatment of inflammatory conditions such as rheumatoid arthritis and osteoarthritis, its clinical use has been largely superseded by other NSAIDs. In recent clinical research contexts, particularly in China, it has been investigated as an adjunct analgesic in multimodal anesthesia regimens. For instance, it has been evaluated alongside agents like oliceridine, alfentanil, and dexmedetomidine to provide perioperative analgesia and potentially mitigate adverse events such as respiratory depression and hemodynamic instability during procedural sedation for gastrointestinal endoscopy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cicloprofen.